Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ublituximab + umbralisib + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- TG Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
U2-CHOP is an investigational chemoimmunotherapy regimen consisting of ublituximab, umbralisib, and CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). Ublituximab is a glycoengineered anti-CD20 monoclonal antibody designed with low fucose content to enhance antibody-dependent cellular cytotoxicity (ADCC). Umbralisib is a dual inhibitor of PI3K-delta and casein kinase 1 (CK1) epsilon. This combination is being evaluated in a Phase Ib/II clinical trial led by the University of Alabama at Birmingham for the treatment of previously untreated mantle cell lymphoma (MCL). The regimen typically involves an induction phase with U2-CHOP followed by a maintenance phase with the U2 (ublituximab and umbralisib) combination. The multi-targeted approach aims to deplete B-cells, inhibit B-cell receptor signaling, and induce cytotoxic DNA damage.
- Other names
- U2-CHOPU-2-CHOPU 2-CHOPU2-CHOP-U2U-2-CHOP-U2U 2-CHOP-U2
02
Targets
CD20 (B-lymphocyte antigen CD20)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)GR (Glucocorticoid receptor)DNAPIK3CD (Phosphatidylinositol 3-kinase delta)TUBB (Tubulin (alpha and beta subunits))CK1 (Casein kinase 1)
Beyond the preview
Go deeper on ublituximab + umbralisib + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ublituximab + umbralisib + cyclophosphamide + doxorubicin + vincristine + prednisone.